Enabling Projects

Start Date

Project Title

Principle Investigator(s)

Total Project Funding

April 1, 2020

Enabling a Phase I/II multicenter clinical trial of a novel single domain (sd)CD22-specific camelid-derived chimeric antigen receptor (CAR) T-cell therapy

Kevin Hay, BC Cancer

BioCanRx funding: $450,000

Partner contributions:

§ BC Cancer Foundation

$ 300,000

§ National Research Council of Canada

$200,000 (in-kind)

Total Funding: $950,000

Robert Holt, BC Cancer

Brad Nelson, BC Cancer

July 1, 2020

Development of a virally programmed exosome-based cancer vaccine platform

Carolina Ilkow, The Ottawa Hospital Research Institute

BioCanRx funding: $616,500

Partner contributions:

§ Canadian Cancer Society

$ 150,000

§ McMaster University

$60,000

§ The Ottawa Hospital Research Institute

$120,000

§ Ontario Institute for Cancer Research

$140,000 (cash & in-kind)

§ FACIT

$1,045,000 (cash & in-kind)

§ Terry Fox Research Institute

$180,000

Total Funding: $2,311,500

Brian Lichty, McMaster University

John Bell, The Ottawa Hospital Research Institute

July 1, 2020

First in human THINKK adoptive immuno-therapy to prevent leukemia and neuro-blastoma relapse: GMP-manufacturing and Phase I clinical trial initiation

Michel Duval, CHU Sainte-Justine

BioCanRx funding: $445,500

Partner contributions:

§ CHU Ste-Justine/Charles Bruneau Foundation

$ 495,000 (cash & in-kind)

Total Funding: $940,500

July 1, 2020

Development of Supporting Analytical Assays and Regulatory Compliance Package for Viral Sensitizer Technology Commercialization

Jean-Simon Diallo, Ottawa Hospital Research Institute

BioCanRx funding: $449,829

Partners:

§ TBA: $566,304

Total Funding: $1,016,133

Christopher Boddy, University of Ottawa

Jeffrey Smith, Carleton University

October 1, 2020

Clinical Trial Enabling Studies for Multi-targeted Chimeric Antigen Receptor Therapeutics for the treatment of B-Cell Malignancies

Scott McComb, National Research Council of Canada/
University of Ottawa

BioCanRx funding: $450,000

Partners:

§ BC Cancer Foundation

$200,000 (in-kind)

§ TBA

$300,000

Total Funding: $950,000

Natasha Kekre,

Ottawa Hospital Research Institute

Robert Holt, BC Cancer

John Webb, BC Cancer

Kevin Hay, BC Cancer

October 1, 2020

Recombinant TCRs to target KRAS hotspot mutations in pancreatic cancer

Robert Holt, BC Cancer

BioCanRx funding: $450,000

Partner contributions:

§ BC Cancer Foundation

$ 480,000

§ Chaire Roger Des Groseillers d’oncologie chirurgicale
hépato-biliaire et pancréatique de l’Université de Montréal

$20,000

Total Funding: $950,000

Simon Turcotte, Université de Montréal

 

Clinical, Social, & Economic Impact (CSEI) Projects

Start Date

Project Title

Principle Investigator(s)

Total Project Funding

March 26, 2019

Using real-world data and iterative economic evaluation to prioritize resource allocation for care and research in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
***

Kednapa Thavorn, The Ottawa Hospital Research Institute

BioCanRx funding: $100,000

Partner contributions:

§ Ontario Institute for Cancer Research

$184,955

§ ICES

§ Ottawa Methods Centre

§ The Ottawa Hospital Research Institute

Total Funding: $284,955

Harry Atkins, The Ottawa Hospital Research Institute

Natasha Kekre, The Ottawa Hospital Research Institute

April 1, 2019

Assessing the Real-World Clinical and Economic Outcomes of Emerging Innovative Technologies in Oncology: The Cases of Biosimilars and CAR T-cells
***

Kelvin Chan, Sunnybrook Research Institute

BioCanRx funding: $100,000

Partner contributions:

§ Ontario Institute for Cancer Research

$197,217

§ Ontario Health (Cancer Care Ontario)

$40,540 (in-kind)

§ Canadian Centre for Applied Research in Cancer Control

$11,160 (in-kind)

Total Funding: $348,917

Scott Gavura, Ontario Health

Wanrudee Isaranuwatchai, Unity Health

July 1, 2020

Identifying effect modifiers for CAR-T cell therapeutic efficacy

Dean Fergusson, The Ottawa Hospital Research Institute

BioCanRx funding: $100,058

Partner contributions:

§ Ottawa Methods Centre

$50,000 (in-kind)

§ Cell Therapy Transplant Canada $10,000 (in-kind)

§ Leukemia & Lymphoma Society of Canada

$10,000 (in-kind)

§ BLUEPRINT Translational Research Group

$10,000 (in-kind)

§ National Research Council of Canada $10,000 (in-kind)

Total Funding: $190,058

October 1, 2020

Making Patient Partnerships A Reality in Very Early Phase Clinical Trials (MARVEL): Development of a Patient Engagement Platform

Manoj Lalu, The Ottawa Hospital Research Institute

BioCanRx funding: $361,490

Partners:

§ TBA

Total Funding: $361,490

Dean Fergusson, The Ottawa Hospital Research Institute

Justin Presseau, The Ottawa Hospital Research Institute

*** The funding for these projects was announced on an earlier date.

 

Clinical Trial Projects

Start Date

Project Title

Principle Investigator(s)

Total Project Funding

April 1, 2020

COV-IMMUNO- A randomized phase III trial of vaccination with IMM-101 versus observation for the prevention of serious respiratory and COVID-19 related infections in cancer patients
***

Rebecca Auer, The Ottawa Hospital

BioCanRx funding: $750,000

Partner contributions:

§ Immodulon Therapeutics

$400,000 (in-kind)

§ Canadian Centre for Applied Research in Cancer Control

$50,000

§ The Ottawa Hospital Foundation

$25,000

§ Ontario Institute for Cancer Research (OICR)

$100,000 (in-kind)

§ The Ottawa Hospital Academic Medical Organization

$96,000

§ ATGen

$44,500 (in-kind)

§ Canadian Cancer Trials Group (CCTG)/ Canadian Cancer
Society

$1,368,611 (cash + in-kind)

Total Funding: $2,834,111

Christopher O’Callaghan, Queen’s University

April 1, 2020

Phase II CYTOSHRINK Trial: Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab and Nivolumab for Metastatic Kidney Cancer

Aly-Khan Lalani, McMaster University

BioCanRx funding: $489,872

Partner contributions:

§ Bristol-Myers Squibb

$774,349

§ Ontario Clinical Oncology Group

$77,435 (cash & in-kind)

Total Funding: $1,341,656

Jonathan Bramson, McMaster University

Michael Surette, McMaster University

October 1, 2020

The Selected Tumor-infiltrating lymphocyte Against Refractory Melanoma-01 Trial (STAR-M01)

Simon Turcotte, Centre hospitalier de l’Université de
Montréal

BioCanRx funding: $675,000

Total partner funding: $2,305,850

§ Iovance Biotherapeutics

§ Institut du cancer de Montréal

§ Centre de Recherche du Centre Hospitalier de l’Université
de Montréal/ Centre Hospitalier de l’Université de Montréal

§ Héma-Québec

§ Canada Research Chair in Patient and Public Partnership

Total Funding: $2,980,850

October 1, 2020

An interventional, open-label, nonrandomized dose-escalation Phase I multicenter clinical trial of multi-peptide anti-minor histocompatibility antigen immunotherapy for the prevention of relapse in patients with high-risk malignancy eligible for matched related ASCT

Denis Claude Roy, Hôpital Maisonneuve-Rosemont

BioCanRx funding: $675,000

Partner contributions:

§ HMR-CIUSSS-East-of-Montreal $800,000

§ CellCAN

$20,000

§ C3i

$100,000 (in-kind)

Total Funding: $1,595,000

*** The funding for these projects was announced on an earlier date.

 

Core & Biomanufacturing Facilities

CORE FACILITIES

Start Date

Project Title

Principle Investigator(s)

Total Project Funding

April 1, 2020

Molecular & Cellular Immunology Core (MCIC), BC Cancer
Deeley Research Centre

Brad Nelson, BC Cancer

BioCanRx funding: $300,000

July 1, 2020

Human Immune Testing Suite (McMaster University)

Jonathan Bramson, McMaster University

BioCanRx funding: $283,366


BIOMANUFACTURING FACILITIES

September 1, 2020

Alberta Cell Therapy Manufacturing Centre

Gregory Korbutt, University of Alberta

BioCanRx funding: $3,391,004

Partner contributions:

§ TBA: $4,499,380

Total Funding: $7,890,384

September 1, 2020

Conconi Family Immunotherapy Lab

Brad Nelson, BC Cancer

John Webb, BC Cancer

September 1, 2020

The Ottawa Hospital Biotherapeutics Manufacturing Centre

John Bell, The Ottawa Hospital Research Institute

October 31, 2020

Three New Point-of-Care Manufacturing Sites; locations TBA

TBA